Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Valiltramiprosate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alzheon Validate Valiltramiprosate Mechanism In Alzheimer Disease
    Alzheon Validate Valiltramiprosate Mechanism In Alzheimer Disease

    03 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260203941149/en/Alzheon-Reports-Plasma-Biomarker-Results-from-Phase-3-and-2-Studies-of-ValiltramiprosateALZ-801-Validating-Its-First-in-Class-Mechanism-of-Action-and-Underscoring-Benefits-in-Cognition-Function-and-Brain-Volume-Protection-in-Alzheimers-Patients

    BUSINESSWIRE
    03 Feb 2026
    Share Share
    Alzheon To Unveil Oral Valiltramiprosate Results At CTAD
    Alzheon To Unveil Oral Valiltramiprosate Results At CTAD

    19 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125136522/en/Alzheon-to-Present-Multiple-Clinical-Neuroimaging-and-Modeling-Results-for-Oral-ValiltramiprosateALZ-801-from-Phase-2-and-3-Studies-at-CTAD-Conference-in-San-Diego-December-14-2025

    BUSINESSWIRE
    19 Nov 2025
    Share Share
    Alzheon Publishes APOLLOE4 Ph3 Data on Oral ALZ-801 in Early AD
    Alzheon Publishes APOLLOE4 Ph3 Data on Oral ALZ-801 in Early AD

    14 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251014241744/en/Alzheon-Announces-Peer-Reviewed-Scientific-Publication-of-Results-from-Pivotal-APOLLOE4-Phase-3-Trial-of-Oral-ValiltramiprosateALZ-801-in-APOE44-Homozygous-Individuals-with-Early-Alzheimers-Disease

    BUSINESSWIRE
    14 Oct 2025
    Share Share
    Alzheon to Present ALZ-801 Data at AAIC Toronto
    Alzheon to Present ALZ-801 Data at AAIC Toronto

    15 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250715240263/en/Alzheon-to-Present-Insights-into-Oral-ValiltramiprosateALZ-801-Mode-of-Action-and-Clinical-Efficacy-at-Dedicated-Symposium-at-Alzheimers-Association-International-Conference-in-Toronto-on-July-30th-2025

    BUSINESSWIRE
    15 Jul 2025
    Share Share
    Alzheon To Present APOLLOE4 Ph3 Data At ADPD On April 1
    Alzheon To Present APOLLOE4 Ph3 Data At ADPD On April 1

    18 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250318710720/en/Alzheon-to-Present-Results-from-Pivotal-APOLLOE4-Phase-3-Trial-of-Oral-ValiltramiprosateALZ-801-at-Dedicated-Symposium-at-ADPD-Conference-in-Vienna-on-April-1st-2025

    BUSINESSWIRE
    18 Mar 2025
    Share Share
    Alzheon Publishes Two Papers Ahead Ph 3 Topline Data At ADPD
    Alzheon Publishes Two Papers Ahead Ph 3 Topline Data At ADPD

    25 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250225250957/en

    BUSINESSWIRE
    25 Feb 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.